Gold prices steady ahead of Fed decision, Trump’s tariff deadline
OnKure Therapeutics, Inc. (NASDAQ:OKUR) President and CEO Nicholas A. Saccomano recently sold shares of the company's Class A Common Stock, according to a recent SEC filing. The company, currently valued at $41 million in market capitalization, has seen its stock decline over 83% in the past year, with InvestingPro analysis suggesting the shares are currently trading below their Fair Value. The transactions, which occurred on April 4 and April 7, involved the sale of 874 shares for a total value of $2,569.
The sales were executed at weighted average prices ranging between $2.671 and $3.3276 per share. These transactions were part of automatic sales to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) under the company's 2023 RSU Equity Incentive Plan.
Following these transactions, Saccomano holds 3,682 shares of OnKure Therapeutics. With the stock trading near its 52-week low of $2.57, investors seeking deeper insights can access 15 additional exclusive ProTips and comprehensive financial metrics through InvestingPro.
In other recent news, OnKure Therapeutics has been the subject of attention following updates from two analyst firms. H.C. Wainwright adjusted its price target for OnKure Therapeutics to $34.00, a decrease from the previous $40.00, while maintaining a Buy rating. This adjustment comes after the presentation of initial results for OnKure's lead candidate, OKI-219, which is in Phase 1 trials for solid tumors. Despite the lack of objective responses in patients at the 900mg dose level, the drug was well-tolerated with only mild adverse events reported. Meanwhile, Jones Trading initiated coverage on OnKure with a Buy rating and set a price target of $32.00. The firm emphasized the significance of OnKure's focus on precision oncology and the potential of OKI-219 in targeting specific mutations. Both firms express confidence in OnKure's research and development efforts, reflecting optimism about future developments in the oncology market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.